LNTH · Lantheus Holdings, Inc.
$100.77
+0.30 (+0.30%)
At close · Aug 28
Market Cap
$6.58B
Shares
65.27M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.54B
+0.5%
FY2025
Net Income
$233.56M
-25.2%
FY2025
Gross Margin
61.1%
-3.3pp
FY2025
Operating Margin
20.16%
-9.6pp
FY2025
Diluted EPS
$3.41
-21.8%
FY2025
Operating Cash Flow
$390.14M
-28.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.4B – $1.45B | $1.56B | $1.54BG | $1.53BG | $1.3BG | $935.06MG | $425.21M | $339.41M | $347.34M | $343.37M | $331.38M | $301.85M | $293.46M | $301.6M | $283.67M | |
| — | $620.3M | $599.66M | $545.62M | $586.89M | $353.36M | $237.51M | $200.65M | $172.53M | $168.49M | $169.24M | $164.07M | $157.94M | $176.08M | $206.31M | |
| — | $936.02M | $941.95M | $988.29M | $709.54M | $581.7M | $187.7M | $138.76M | $174.81M | $174.89M | $162.14M | $137.78M | $135.52M | $125.52M | $77.36M | |
| — | — | 61.1% | 64.43% | 54.73% | 62.21% | 44.14% | 40.88% | 50.33% | 50.93% | 48.93% | 45.64% | 46.18% | 41.62% | 27.27% | |
| — | $173.09M | $177.31M | $168.1M | $77.71M | $311.68M | $44.97M | $32.79M | $20.02M | $17.07M | $18.13M | $12.2M | $14.36M | $13.67M | $30.46M | |
| — | $230.64M | $178.69M | $177.94M | $141.74M | $100.24M | $68.42M | $40.9M | $41.89M | $43.16M | $42.32M | $36.54M | $34.74M | $35.12M | $35.23M | |
| — | $229.96M | $275.12M | $193.69M | $125.46M | $133.58M | $150.4M | $69.27M | $61.24M | $50.17M | $49.84M | $38.83M | $43.89M | $37.31M | $33.04M | |
| — | $64.5M | $47.1M | $43.8M | $46.4M | $33.2M | $27.5M | $10.8M | $1.8M | $2.6M | $3.3M | $5.1M | $6M | $7.6M | $14.4M | |
| — | $88.51M | $70.1M | $64.62M | $60.04M | $47.93M | $42.29M | $24.69M | $13.38M | $13.93M | $19.23M | $18.26M | $19.65M | $19.02M | $25.78M | |
| — | — | $12.1M | $9.4M | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $0 | $0 | $912K | $0 | $0 | — | — | |
| — | — | — | — | — | — | — | $142.96M | $123.15M | $110.4M | $110.28M | — | $92.99M | $86.1M | $96.25M | |
| — | $302.34M | $310.83M | $456.98M | $364.64M | $36.2M | -$60.83M | -$4.2M | $51.66M | $64.49M | $51.85M | $56.59M | $42.53M | $39.42M | -$18.89M | |
| — | — | 20.16% | 29.79% | 28.13% | 3.87% | -14.3% | -1.24% | 14.87% | 18.78% | 15.65% | 18.75% | 14.49% | 13.07% | -6.66% | |
| — | $390.85M | $380.93M | $521.6M | $424.69M | $84.12M | -$18.54M | $20.49M | $65.04M | $78.42M | $71.08M | $74.85M | $62.18M | $58.44M | $6.89M | |
| — | $19.81M | $19.75M | $19.67M | $20.02M | $7.19M | $7.75M | $9.48M | $13.62M | $17.41M | $18.41M | $26.62M | $38.72M | $42.29M | $42.92M | |
| — | — | — | $36.84M | $19.64M | $2.61M | $45K | $238K | $686K | $167K | $18K | — | $24K | $27K | $104K | |
| — | $23.88M | $31.33M | $37.23M | $66.32M | -$1.7M | -$7.35M | $2.2M | -$6.22M | $2.47M | $8.64M | $220K | -$65K | $505K | $1.16M | |
| — | $362.98M | $313.79M | $430.98M | $410.94M | $26.72M | -$75.04M | -$11.48M | $28.63M | $49.55M | $39.64M | $28.29M | -$11.78M | -$2.37M | -$60.54M | |
| — | $87.67M | $80.23M | $118.54M | $84.28M | -$1.35M | -$3.76M | $1.99M | -$3.04M | $9.03M | -$83.75M | $1.53M | $2.97M | $1.2M | $1.01M | |
| — | $275.31M | $233.56M | $312.44M | $326.66M | $28.07M | -$71.28M | -$13.47M | $31.67M | $40.52M | $123.39M | — | — | — | — | |
| — | — | 15.15% | 20.37% | 25.2% | 3% | -16.76% | -3.97% | 9.12% | 11.8% | 37.23% | — | — | — | — | |
| — | $275.31M | $233.56M | $312.44M | $326.66M | $28.07M | -$71.28M | — | — | $40.52M | $123.39M | $26.76M | -$14.75M | -$3.56M | -$61.56M | |
| — | $274.62M | $233.87M | $311.86M | $326.88M | $27.29M | -$69.72M | -$14.56M | $31.82M | $40.44M | $123.3M | $27.8M | -$15.1M | -$4.8M | -$63.28M | |
| USD/shares | — | $4.23 | $3.46 | $4.52 | $4.79 | $0.41 | -$1.06 | -$0.25 | $0.81 | $1.06 | $3.31 | $0.84 | -$0.60 | -$0.20 | — |
| USD/shares | $5.00 – $5.25* | $4.18 | $3.41G | $4.36G | $4.65G | $0.40G | -$1.06 | -$0.25 | $0.79 | $1.03 | $3.17 | $0.82 | -$0.60 | -$0.20 | — |
| shares | — | — | 67.49M | 69.2M | 68.27M | 68.49M | 67.49M | 54.13M | 38.99M | 38.23M | 37.28M | 32.04M | 24.44M | 18.08M | 18.03B |
| shares | — | — | 68.44M | 71.65M | 70.24M | 70.67M | 67.49M | 54.13M | 40.11M | 39.5M | 38.89M | 32.66M | 24.44M | 18.08M | 18.03B |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2013–FY2025: $475.12M in buybacks, $123K in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
4.21×
Peer median 2.58×
EV/EBIT
21.68×
Peer median 20.91×
P/E (TTM)
24.11×
Peer median 17.79×
Peer medians compare against the 33 similar-size Drug Manufacturers - Specialty & Generic companies (of 98 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2020 | FY2019 | FY2018 |
|---|---|---|---|
| US Segment | $294,796,000 | $303,989,000 | $288,580,000 |
| International Segment | $44,614,000 | $43,348,000 | $54,794,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| United States | $1,458,881,000 | $1,484,687,000 | $1,262,146,000 |
| Non Us | $82,728,000 | $49,223,000 | $34,283,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $1,507,573,000 | $1,524,782,000 | $1,263,068,000 | $887,038,000 | $400,356,000 | — | — | — |
| PYLARIFY | $989,116,000 | $1,057,834,000 | $851,303,000 | $527,405,000 | $43,414,000 | $0 | $0 | — |
| Radiopharmaceutical Oncology | $989,116,000 | $1,058,218,000 | $854,433,000 | $531,507,000 | $48,887,000 | $10,022,000 | $8,655,000 | — |
| Total Precision Diagnostics | $493,114,000 | $437,510,000 | $390,118,000 | $356,682,000 | $351,025,000 | $317,634,000 | $337,106,000 | — |
| Definity | $330,248,000 | $317,792,000 | $279,768,000 | $244,993,000 | $232,759,000 | $195,865,000 | $202,398,000 | $183,073,000 |
| TechneLite | $86,803,000 | $95,487,000 | $87,370,000 | $88,864,000 | $91,293,000 | $84,945,000 | $85,465,000 | $98,858,000 |
| Strategic Partnerships and Other | $59,379,000 | $38,182,000 | $51,878,000 | $46,872,000 | $25,296,000 | $11,754,000 | $1,576,000 | — |
| Neuraceq | $51,447,000 | $0 | $0 | — | — | — | — | — |
| License and Royalty Revenues | $34,036,000 | $9,128,000 | $33,361,000 | $48,023,000 | $24,852,000 | $11,715,000 | $2,061,000 | — |
| Other Precision Diagnostics | $24,616,000 | $24,231,000 | $22,980,000 | $22,825,000 | $26,973,000 | $36,824,000 | $49,243,000 | — |
| Other Radiopharmaceutical Oncology | $0 | $384,000 | $3,130,000 | $4,102,000 | $5,473,000 | $10,022,000 | $8,655,000 | — |
| License and Royalty Revenues Sales Based Milestone Payment | — | $0 | — | — | — | — | — | — |
| Other Nuclear | — | — | — | — | — | $58,924,000 | $59,805,000 | $74,284,000 |
| Product Revenue Net | — | — | — | $887,038,000 | $400,356,000 | $327,695,000 | $345,276,000 | — |
| Rebates and Allowances | — | — | — | — | — | -$19,071,000 | -$16,568,000 | -$12,841,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2020 | FY2019 | FY2018 |
|---|---|---|---|
| International Segment | $6,165,000 | $7,386,000 | $8,161,000 |
| US Segment | -$10,363,000 | $44,275,000 | $56,327,000 |
Operating Margin by Segment (%)
| Component | FY2020 | FY2019 | FY2018 |
|---|---|---|---|
| US Segment | -3.5% | 14.6% | 19.5% |
| International Segment | 13.8% | 17% | 14.9% |
Key facts
CIK
1521036
CUSIP
516544103
13F (30d)
333 filings
329 filers
Visit website
Investor relations